宫炎平胶囊对小鼠解脲支原体性生殖道炎症和生育能力的影响  

Effects of Gongyanping Capsule on genital tract infected by ureaplasma urealyticum and fertility of mice

作　　者：杨帆[1] 杨磊[2] 杨鉴冰 郑雪绒 张建华[1] 田颖 张朝红[5] 张瑾[1] Yang Fan;Yang Lei;Yang Jianbing;Zheng Xuerong;Zhang Jianhua;Tian Ying;Zhang Chaohong;Zhang Jin(Department of Obstetrics and Gynecology,the Second Affiliated Hospital of Xi'an Medical College,Xi'an 710038,China;Department of Neurosurgery,the Second Affiliated Hospital of Xi'an Medical College,Xi'an 710038,China;Department of Gynecology,Affiliated Hospital of Shaanxi University of Traditional Chinese Medicine,Xianyang 712046,China;Department of Gynecology,Shaanxi Academy of Traditional Chinese Medicine Shaanxi Provincial Hospital of Chinese Medicine,Xi'an 710000,China;Department of Obstetrics and Gynecology,Baoji Maternity and Child Healthcare Hospital,Baoji 721001,China)

机构地区：[1]西安医学院第二附属医院产二科,西安710038 [2]西安医学院第二附属医院神经外科,西安710038 [3]陕西中医药大学附属医院妇科,咸阳712046 [4]陕西省中医研究院陕西省中医院妇科,西安710000 [5]宝鸡市妇幼保健院妇产科,宝鸡721001

出　　处：《国际中医中药杂志》2022年第11期1259-1264,共6页International Journal of Traditional Chinese Medicine

基　　金：陕西省重点研发计划项目(S2017-ZDYF-YBXM-SF-0221)。

摘　　要：目的观察宫炎平胶囊对小鼠解脲支原体性生殖道炎症和生育能力的影响,并探讨其作用机制。方法将100只雌性ICR小鼠按随机数字表法分为正常对照组、模型对照组、阿奇霉素组及宫炎平胶囊低、高剂量组。除正常对照组外,其余各组利用解脲支原体(Uu)感染建立生殖道炎症模型。阿奇霉素组小鼠阴道给予阿奇霉素40 mg/kg,宫炎平胶囊低、高剂量组小鼠阴道给予宫炎平胶囊50、100 mg/kg,正常对照组、模型对照组给予等体积生理盐水,1次/d,连续给药4周。记录各组生育情况。采用HE染色法观察各组小鼠阴道组织病理学改变,测定各组小鼠阴道单核细胞趋化蛋白1(monocyte chemoattractant protein 1,MCP-1)、IL-4、IL-12、TNF-α、髓过氧化物酶(myeloperoxidase,MPO)、GSH-Px水平;采用RT-PCR法及Western blot法测定小鼠阴道TLR4、NF-κB mRNA和蛋白表达水平。结果与模型对照组比较,阿奇霉素组及宫炎平胶囊低、高剂量组小鼠生育时间、鼠仔死亡数降低,产仔数增多(P<0.05),阴道组织MCP-1、MPO、IL-4、IL-12、TNF-α水平降低(P<0.05),GSH-Px水平升高(P<0.05),TLR4 mRNA[(1.25±0.33)、(2.97±0.92)、(2.32±0.72)比(3.69±1.32)]、NF-κB mRNA[(1.48±0.42)、(2.91±0.99)、(2.13±0.70)比(3.83±1.41)]水平降低(P<0.05),TLR4[(0.63±0.13)、(1.32±0.34)、(1.04±0.33)比(1.63±0.41)]、NF-κB[(0.63±0.14)、(1.36±0.32)、(1.03±0.30)比(1.94±0.58)]蛋白表达降低(P<0.05),且具有一定的剂量依赖性。结论宫炎平胶囊对小鼠Uu感染生殖道炎症具有明显治疗作用,可提高小鼠生育能力,其机制可能与宫炎平胶囊抑制小鼠阴道TLR4/NF-κB通路激活有关。Objective To observe the effect of Gongyanping Capsule on genital tract infected by ureaplasma urealyticum and fertility of mice,and to explore its mechanism.Methods One hundred female ICR mice were divided into normal control group,model control group,azithromycin group,the low and high-dose group of Gongyanping Capsule according to random number table method.Except for the normal control group,the other groups were infected with ureaplasma urealyticum to establish the reproductive tract inflammation model.The azithromycin group was given 40 mg/kg of azithromycin,the low and high-dose groups were given 50 and 100 mg/kg of Gongyanping Capsule respectively,the normal control group and model control group were given equal volume of normal saline,once a day,for 4 consecutive weeks.The fertility status of each group was recorded.HE staining was used to observe the pathological changes of the vaginal tissues of the mice in each group,and the content of monocyte chemoattractant protein 1(MCP-1),IL-4,IL-12,TNF-αmyeloperoxidase(MPO)and GSH-Px of the mice in each group were determined;RT-PCR and Western blot were used to determine the vagina level of mRNA and protein expressions of TLR4 and NF-κB.Results Compared with the model control group,the birth time and the number of dead mice in the azithromycin group and the low and high dose groups of Gongyanping Capsule decreased(P<0.05),and the number of born mice increased(P<0.05).The level of MCP-1,MPO,IL-4,IL-12,TNF-αdecreased(P<0.05),the level of GSH-Px increased(P<0.05),the expression of TLR4 mRNA(1.25±0.33,2.97±0.92,2.32±0.72 vs.3.69±1.32),NF-κB mRNA(1.48±0.42,2.91±0.99,2.13±0.70 vs.3.83±1.41)decreased(P<0.05),the expression of TLR4(0.63±0.13,1.32±0.34,1.04±0.33 vs.1.63±0.41),NF-κB(0.63±0.14,1.36±0.32,1.03±0.30 vs.1.94±0.58)decreased(P<0.05),and had a certain dose-dependence.Conclusion Gongyanping Capsule has obvious therapeutic effect on genital tract mice infected by ureaplasma urealyticum,and can significantly improve the fertility of mice;the mec

关 键 词：解脲支原体 生殖道感染 炎症 生育力 宫炎平胶囊 小鼠 

分 类 号：R285.5[医药卫生—中药学]